Neuroregulation of the Hypothalamus-Pituitary-Adrenal (HPA) Axis in Humans: Effects of GABA-, Mineralocorticoid-, and GH-Secretagogue-Receptor Modulation

The hypothalamus-pituitary-adrenal (HPA) axis exerts a variety of effects at both the central and peripheral level. Its activity is mainly regulated by CRH, AVP, and the glucocorticoid-mediated feedback action. Moreover, many neurotransmitters and neuropeptides influence HPA axis activity by acting at the hypothalamic and/or suprahypothalamic level. Among them, GABA and Growth Hormone Secretagogues (GHS)/GHS-receptor systems have been shown to exert a clear inhibitory and stimulatory effect, respectively, on corticotroph secretion. Alprazolam (ALP), a GABA-A receptor agonist, shows the most marked inhibitory effect on both spontaneous and stimulated HPA axis activity, in agreement with its peculiar efficacy in panic disorders and depression where an HPA axis hyperactivation is generally present. Ghrelin and synthetic GHS possess a marked ACTH/cortisol-releasing effect in humans and the ghrelin/GHS-R system is probably involved in the modulation of the HPA response to stress and nutritional/metabolic variations. The glucocorticoid-mediated negative feedback action is mediated by both glucocorticoid (GR) and mineralocorticoid (MR) receptors activation at the central level, mainly in the hippocampus. In agreement with animal studies, MRs seem to play a crucial role in the maintenance of the circadian ACTH and cortisol rhythm, through the modulation of CRH and AVP release. GABA agonists (mainly ALP), ghrelin, as well as MR agonists/antagonists, may represent good tools to explore the activity of the HPA axis in both physiological conditions and pathological states characterized by an impaired control of the corticotroph function.

[1]  M. Papotti,et al.  Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland , 2001, Journal of endocrinological investigation.

[2]  S. Al-Damluji,et al.  Stress and the pituitary-adrenal axis. , 1987, Bailliere's clinical endocrinology and metabolism.

[3]  R. Sapolsky,et al.  The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. , 1991, Endocrine reviews.

[4]  L. Jacobson,et al.  Hypothalamic-pituitary-adrenocortical axis regulation. , 2005, Endocrinology and metabolism clinics of North America.

[5]  S. Grottoli,et al.  Elderly subjects show severe impairment of dehydroepiandrosterone sulphate and reduced sensitivity of cortisol and aldosterone response to the stimulatory effect of ACTH1−24 , 2001, Clinical endocrinology.

[6]  M. Korbonits,et al.  The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. , 2001, The Journal of clinical endocrinology and metabolism.

[7]  S. Iversen,et al.  Handbook of Psychopharmacology , 1988, Springer US.

[8]  S. Grottoli,et al.  Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin‐induced hypoglycaemia in humans , 2003, Clinical endocrinology.

[9]  M. Tschöp,et al.  Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. , 2004, Endocrine reviews.

[10]  R. N. Brogden,et al.  Alprazolam , 1984, Drugs.

[11]  E. Arvat,et al.  The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease. , 2005, European journal of endocrinology.

[12]  M. Fujimiya,et al.  A Role of Ghrelin in Neuroendocrine and Behavioral Responses to Stress in Mice , 2001, Neuroendocrinology.

[13]  E. Ghigo,et al.  The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state , 2004, Clinical endocrinology.

[14]  J. Funder.  Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. , 1997, Annual review of medicine.

[15]  E. Arvat,et al.  Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women , 1998, Journal of endocrinological investigation.

[16]  D. Orth.  Corticotropin-releasing hormone in humans. , 1992, Endocrine reviews.

[17]  Philip W. Gold,et al.  The hypothalamic-pituitary-adrenal axis in anorexia nervosa , 1996, Psychiatry Research.

[18]  R. Pasquali,et al.  Activity of the hypothalamic–pituitary–adrenal axis in different obesity phenotypes , 2000, International Journal of Obesity.

[19]  F. Holsboer,et al.  Sleep endocrine effects of antigluco- and antimineralocorticoids in healthy males. , 1994, The American journal of physiology.

[20]  F. Casanueva,et al.  Ghrelin Is No Longer Able to Stimulate Growth Hormone Secretion in Patients with Cushing’s Syndrome but Instead Induces Exaggerated Corticotropin and Cortisol Responses , 2002, Neuroendocrinology.

[21]  P. S. Wang,et al.  Glucocorticoids and aging. , 1997, Journal of the Formosan Medical Association = Taiwan yi zhi.

[22]  G. Migliaretti,et al.  Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralocorticoid receptor blockade. , 2005, The Journal of clinical endocrinology and metabolism.

[23]  Márta Korbonits,et al.  The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. , 2002, The Journal of clinical endocrinology and metabolism.

[24]  H. Akil,et al.  Mineralocorticoid receptor function in major depression. , 2003, Archives of general psychiatry.

[25]  J. Born,et al.  Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. , 1991, The American journal of physiology.

[26]  M. Korbonits,et al.  Ghrelin—a hormone with multiple functions , 2004, Frontiers in Neuroendocrinology.

[27]  P. Vonvoigtlander,et al.  Alprazolam: Review of pharmacological, pharmacokinetic, and clinical data , 1985 .

[28]  E. Arvat,et al.  The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. , 1999, The Journal of clinical endocrinology and metabolism.

[29]  E. Arvat,et al.  Effects of Dexamethasone and Alprazolam, a Benzodiazepine, on the Stimulatory Effect of Hexarelin, a Synthetic GHRP, on ACTH, Cortisol and GH Secretion in Humans , 1998, Neuroendocrinology.

[30]  V. Papadopoulos.  Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: biological role in steroidogenic cell function. , 1993, Endocrine reviews.

[31]  G. Arnaldi,et al.  Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors. , 2003, The Journal of clinical endocrinology and metabolism.

[32]  J. Skerritt,et al.  Differences in the interactions between GABA and benzodiazepine binding sites , 1982, Neuroscience Letters.

[33]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[34]  E. O. Johnson,et al.  Effects of peripheral benzodiazepine receptor ligands on hypothalamic-pituitary-adrenal axis function in the rat. , 1990, The Journal of pharmacology and experimental therapeutics.

[35]  C. Havard,et al.  The effect of diazepam on pituitary function in man. , 1972, The Journal of endocrinology.

[36]  J. Roberts,et al.  Molecular and Pharmacological Characterization of GABAA Receptors in the Rat Pituitary , 1994, Journal of neurochemistry.

[37]  G. Makara,et al.  Corticosterone and dexamethasone act at different brain sites to inhibit adrenalectomy-induced adrenocorticotropin hypersecretion , 1988, Brain Research.

[38]  E. Arvat,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Mineralocorticoid Receptor Blockade by Canrenoate Increases Both Spontaneous and Stimulated Adrenal Function in Humans* , 2022 .

[39]  S. Grottoli,et al.  Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans , 2002, Journal of endocrinological investigation.

[40]  A. Ratka,et al.  On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. , 1989, Neuroendocrinology.

[41]  S. Grottoli,et al.  Effects of Alprazolam, a Benzodiazepine, on the ACTH-, GH- and PRL-Releasing Activity of Hexarelin, a Synthetic Peptidyl GH Secretagogue (GHS), in Patients with Simple Obesity and in Patients with Cushing's Disease , 1999, Pituitary.

[42]  S. Grottoli,et al.  The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. , 2002, The Journal of clinical endocrinology and metabolism.

[43]  B. McEwen,et al.  The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. , 1986, Endocrine reviews.

[44]  T. Seeman,et al.  Aging and hypothalamic-pituitary-adrenal response to challenge in humans. , 1994, Endocrine reviews.

[45]  M. Papotti,et al.  Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor , 2005, Clinical endocrinology.

[46]  N. Pivac,et al.  Inhibitory effect of diazepam on the activity of the hypothalamic-pituitary-adrenal axis in female rats , 2005, Journal of Neural Transmission / General Section JNT.

[47]  E. Peskind,et al.  Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. , 1997, Neuroendocrinology.

[48]  C. Braestrup,et al.  Benzodiazepine receptors. , 1985, Clinical neuropharmacology.

[49]  D. Charney,et al.  Intravenous diazepam fails to change growth hormone and cortisol secretion in humans , 1986, Psychiatry Research.

[50]  E. Arvat,et al.  Corticotropin-Releasing Effect of Hexarelin, a Peptidyl GH Secretagogue, in Normal Subjects Pretreated with Metyrapone or RU-486, a Glucocorticoid Receptor Antagonist, and in Patients with Addison’s Disease , 1999, Neuroendocrinology.

[51]  E. Arvat,et al.  The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations. , 1997, European journal of endocrinology.

[52]  N. Orentreich,et al.  Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. , 1984, The Journal of clinical endocrinology and metabolism.

[53]  E. Ghigo,et al.  Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity. , 2003, The Journal of clinical endocrinology and metabolism.

[54]  E. D. De Souza,et al.  Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing-factor receptors in rat brain and pituitary. , 1989, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[55]  M. Joëls,et al.  Brain corticosteroid receptor balance in health and disease. , 1998, Endocrine reviews.

[56]  G. Chrousos,et al.  In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications. , 1990, The Journal of clinical endocrinology and metabolism.

[57]  S. Grottoli,et al.  Benzodiazepines and anterior pituitary function , 2002, Journal of endocrinological investigation.

[58]  J. Born,et al.  Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. , 2004, The Journal of clinical endocrinology and metabolism.

[59]  E. Arvat,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Adrenocorticotropin- and Cortisol-Releasing Effect of Hexarelin, a Synthetic Growth Hormone-Releasing , 2022 .